Image Credit: STAT News
STAT+: AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty
AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He’d like it to be higher.